Takeda invested $20m in the round and is providing $80m in development financing through a strategic partnership deal.
US-based liver disease therapy startup Ambys Medicines has launched with $60m in series A funding from pharmaceutical firm Takeda and healthcare-focused venture capital firm Third Rock Ventures.
In addition to putting up $20m for the series A round, Takeda is providing a further $80m through a strategic partnership agreement in order to finance Ambys research. Asit Parikh, head of Takeda’s Gastroenterology Therapeutic Area Unit, has taken a seat on the board of directors at Ambys.
Ambys is working on a…
